Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?
- 206 Downloads
Our goal was to determine if whole blood viscosity (WBV) can be used to predict the risk of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc).
Patients with SSc were analyzed. Out of 107 patients, 26 patients, found to have confirmed diagnosis of PAH, were classified as those with (n = 26, PAH group) and without PAH (n = 81, non-PAH group). We calculated estimated WBV at both high (HSR) and low shear rates (LSR) from hematocrit and total serum protein levels.
Total protein levels were significantly higher and the anti-centromere antibody (ACA) was more frequent in the PAH group. Furthermore, anti-topoisomerase antibody (anti-scl-70) was significantly less frequent in the PAH group. The WBV values were significantly higher at HSR (16.68 ± 0.38 vs. 16.24 ± 0.58; p < 0.001) and at LSR (51.81 ± 7.21 vs. 42.97 ± 11.76; p < 0.001) in PAH group. The multivariate analysis revealed that the WBV at both shear rates independently designated the presence of PAH in SSc patients. The ROC curve showed that the sensitivity and specificity of LSR and HSR were 92.3% and 61.7% (AUC 0.759, p < 0.001), and 88.5% and 65.4% (AUC 0.770, p < 0.001) with a cutoff value of 43.56 and 16.32 for WBV, respectively.
• The most important cause of morbidity and mortality in systemic sclerosis patients is considered to be pulmonary arterial hypertension.
• When the symptoms of PAH are not recognized earlier in the course of the SSc, the prognosis might be worse.
• Higher whole blood viscosity levels in scleroderma patients with PAH was an independent indicator for PAH development.
KeywordsPulmonary arterial hypertension Systemic sclerosis Whole blood viscosity
Compliance with ethical standards
- 2.Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093. https://doi.org/10.1136/ard.62.11.1088 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Frances C, Launay D, Mouthon L, Allanore Y, Tiev KP, Clerson P, de Groote P, Humbert M (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52(12):3792–3800. https://doi.org/10.1002/art.21433 CrossRefPubMedGoogle Scholar
- 7.Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A (2012) The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 71(2):249–252. https://doi.org/10.1136/annrheumdis-2011-200265 CrossRefPubMedGoogle Scholar
- 8.Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, Kiely DG, Sabroe I, Rajaram S, Swift AJ, Condliffe R (2017) Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest 152(1):92–102. https://doi.org/10.1016/j.chest.2017.02.010 CrossRefPubMedGoogle Scholar
- 9.Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138(6):1383–1394. https://doi.org/10.1378/chest.10-0260 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Budhiraja R, Tuder RM, Hassoun PM (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109(2):159–165. https://doi.org/10.1161/01.cir.0000102381.57477.50 CrossRefPubMedGoogle Scholar
- 12.Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155(2):411–419. https://doi.org/10.1016/s0002-9440(10)65137-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG (1997) Blood viscosity and risk of cardiovascular events: the Edinburgh artery study. Br J Haematol 96(1):168–173. https://doi.org/10.1046/j.1365-2141.1997.8532481.x CrossRefPubMedGoogle Scholar
- 16.de Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH (1990) Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation 81(1):107–117. https://doi.org/10.1161/01.CIR.81.1.107 CrossRefPubMedGoogle Scholar
- 21.Silber HA, Bluemke DA, Ouyang P, Du YP, Post WS, Lima JA (2001) The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. J Am Coll Cardiol 38(7):1859–1865. https://doi.org/10.1016/S0735-1097(01)01649-7 CrossRefPubMedGoogle Scholar
- 22.Tietjen GW, Chien S, Leroy EC, Gavras I, Gavras H, Gump FE (1975) Blood viscosity, plasma proteins, and Raynaud syndrome. Arch Surg 110(11):1343–1346. https://doi.org/10.1001/archsurg.1975.01360170083011 CrossRefPubMedGoogle Scholar
- 28.Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317 CrossRefPubMedGoogle Scholar
- 32.Ranchoux B, Harvey LD, Ayon RJ, Babicheva A, Bonnet S, Chan SY, Yuan JX, Perez VJ (2018) Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover conference series). Pulm Circ 8(1):2045893217752912. https://doi.org/10.1177/2045893217752912 CrossRefPubMedGoogle Scholar
- 35.Cecchi E, Giglioli C, Valente S, Lazzeri C, Gensini GF, Abbate R, Mannini L (2011) Role of hemodynamic shear stress in cardiovascular disease. Atherosclerosis 214(2):249–256. https://doi.org/10.1016/j.atherosclerosis.2010.09.008 CrossRefPubMedGoogle Scholar
- 36.Korsten P, Niewold TB, Zeisberg M, Utset TO, Cho D, Zachary LS, Sweiss NJ, Volkov S (2017) Increased whole blood viscosity is associated with the presence of digital ulcers in systemic sclerosis: results from a cross-sectional pilot study. Autoimmune diseases 2017(3529214):1–5. https://doi.org/10.1155/2017/3529214 CrossRefGoogle Scholar
- 37.Wei A, Gu Z, Li J, Liu X, Wu X, Han Y, Pu J (2016) Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc 5(11). https://doi.org/10.1161/jaha.116.003896
- 39.Kolstad KD, Li S, Steen V, Chung L (2018) Long-term outcomes in systemic sclerosis-associated pulmonary arterial hypertension from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry (PHAROS). Chest 154(4):862–871. https://doi.org/10.1016/j.chest.2018.05.002 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, Clerson P, Cordier JF, Simonneau G, Humbert M (2013) Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 72(12):1940–1946. https://doi.org/10.1136/annrheumdis-2012-202489 CrossRefPubMedGoogle Scholar
- 41.McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16):2250–2294. https://doi.org/10.1161/circulationaha.109.192230 CrossRefPubMedGoogle Scholar
- 42.Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan JG (2006) Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27(12):1485–1494. https://doi.org/10.1093/eurheartj/ehi891 CrossRefPubMedGoogle Scholar
- 44.Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Muller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Muller A, Seitz C, Schmidt E, Lehmann P, Foeldvari I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Bohm M, Saar P, Fierlbeck G, Kotter I, Lorenz HM, Blank N, Grafenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V (2008) The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford, England) 47(8):1185–1192. https://doi.org/10.1093/rheumatology/ken179 CrossRefGoogle Scholar